在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human B- and T-lymphocyte attenuator(BTLA) ELISA kit

  • 中文名稱:
    人B和T淋巴細胞衰減因子(BTLA)酶聯免疫試劑盒
  • 貨號:
    CSB-EL002868HU
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人B和T淋巴細胞衰減因子(BTLA)酶聯免疫試劑盒(CSB-EL002868HU)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的BTLA含量。BTLA(B 和 T 淋巴細胞衰減因子)是一種重要靶點。它在免疫調節中起關鍵作用,可負向調控淋巴細胞的活化與功能。研究機制主要聚焦于其與配體結合后傳導抑制性信號,影響免疫細胞的增殖、分化及細胞因子分泌,為免疫相關疾病治療帶來新思路。試劑盒檢測范圍為0.45 ng/mL-30 ng/mL,適用于科研領域中對BTLA蛋白水平的定量分析,例如在腫瘤微環境研究、免疫細胞功能探索或實驗性治療方案評估中,檢測不同病理狀態下BTLA的動態變化,為免疫調控機制研究及藥物開發提供實驗依據。本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    B and T lymphocyte associated protein ELISA Kit; B and T lymphocyte attenuator ELISA Kit; B and T lymphocyte associated ELISA Kit; B- and T-lymphocyte attenuator ELISA Kit; B- and T-lymphocyte-associated protein ELISA Kit; BTLA ELISA Kit; BTLA_HUMAN ELISA Kit; BTLA1 ELISA Kit; CD272 ELISA Kit; CD272 antigen ELISA Kit; FLJ16065 ELISA Kit; MGC129743 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    0.45 ng/mL-30 ng/mL
  • 靈敏度:
    0.11 ng/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human BTLA in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
      Sample Serum(n=4)  
    1:1 Average % 87  
    Range % 83-95  
    1:2 Average % 98  
    Range % 92-103  
    1:4 Average % 108  
    Range % 102-115  
    1:8 Average % 95  
    Range % 87-100  
  • 回收率:
    The recovery of human BTLA spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 97 92-102  
    EDTA plasma (n=4) 99 96-106  
                 
                 
  • 標準曲線:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    30 2.167 2.247 2.207 2.107  
    15 1.532 1.456 1.494 1.394  
    7.5 0.928 0.954 0.941 0.841  
    3.75 0.589 0.579 0.584 0.484  
    1.8 0.387 0.401 0.394 0.294  
    0.9 0.286 0.274 0.280 0.180  
    0.45 0.193 0.199 0.196 0.096  
    0 0.101 0.099 0.100    
  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

相關問答

 常見問題解答
Q:

"Is it possible to know how the standard protein attach to wells of the plate form kit CSB-EL002868HU ?
Is the plate pre-treated with an anti-tag antibody ?Or is it simply adsorption to plastic ?"

A:
Thanks for your mail.
This kit uses the double antibody sandwich method, in which the enzyme plate is already pre-coated(mouse monoclonal antibody, physical adsorption),
and then adding the standard/sample (standard: 293 cell-derived recombinant protein).
At this time, the standard/sample and the enzyme labeling antibody that the package is taken to produce the specific reaction of antigen antibody, then the incubate but not wash the plate, after this, adding Biotin- antibody(detection antibody: rat monoclonal), thus it forms the double antibody sandwich principle. Specific experimental principles (principle of the ASSAY) and operating procedures (ASSAY PROCEDURE),pls refer to the attached manual. I will send you manual reference by email later.

靶點詳情

  • 功能:
    Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells.
  • 基因功能參考文獻:
    1. Data suggest that both HVEM and UL144 bind a common epitope of BTLA, whether engaged in trans or in cis; these studies were conducted in cell lines representing B-lymphocytes, T-lymphocytes, and natural killer cells. (HVEM = human herpes virus entry mediator; UL144 = membrane glycoprotein UL144 of Human herpesvirus 5; BTLA = human B- and T-lymphocyte attenuator) PMID: 29061848
    2. our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in hepatocellular carcinoma patients PMID: 30116751
    3. data provide the first evidence that increased BTLA predicts poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL), and blockade of BTLA with other checkpoints may potentially represent a new strategy for immunotherapy of DLBCL. PMID: 29353075
    4. The genetic variants of rs76844316 in BTLA influence the susceptibility to severe chronic hepatitis B and might play a protective role against the progression of chronic hepatitis B. PMID: 29558758
    5. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID: 27412504
    6. Our data portrays BTLA as a molecule with the singular ability to provide both costimulatory and coinhibitory signals to activated CD8(+) T cells, resulting in extended survival, improved tumor control, and the development of a functional recall response. PMID: 28754817
    7. results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies PMID: 27234378
    8. The percentage of circulating BTLA+CD4+ lymphocytes was significantly higher in patients with severe community acquired pneumonia. PMID: 28164546
    9. Plasma concentrations of soluble BTLA were increased early in sepsis/septic shock and correlated to severity of disease. A baseline concentration >21ng/mL was associated with a poor prognosis. PMID: 28056053
    10. this study shows that in chronic hepatitis B virus patients, a subset of inefficient interferon-gamma producing antigen-specific CD8+ T cells recruited to the liver expressed high BTLA levels PMID: 27743606
    11. this study shows that BTLA expression is likely associated with positive rather than conventional negative regulation of CD11c antigen-presenting cell stimulatory capacity PMID: 27717503
    12. rs1982809 BTLA gene polymorphism is associated with mRNA expression level and variations in the BTLA gene might be considered as potentially low-penetrating chronic lymphocytic leukemia risk factor PMID: 27933341
    13. Study showed a decreased expression of BTLA in ocular Behcet's disease suggesting that it may be involved in the development and recurrence of this disease. PMID: 26841832
    14. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. PMID: 26277622
    15. our study confirms that CD200/BTLA deletions are recurrent genetic lesions in the biology of BCP-ALL PMID: 26137961
    16. Focal deletions of the BTLA were associated with B-cell precursor acute lymphoblastic leukemia. PMID: 25261097
    17. high BTLA expression levels in gastric cancer, identified by IHC, are an independent biomarker for the poor prognosis of patients with gastric cancer. PMID: 25334051
    18. Data indicate taht lung function and the expressions of B, T lymphocyte attenuator (BTLA) and Treg cells were lower in patients with rheumatism than those in normal controls. PMID: 24909289
    19. BTLA is a coreceptor that negatively regulates human Vgamma9Vdelta2 T-cell proliferation and has a role in immune escape for lymphoma cells PMID: 23692853
    20. BTLA and HVEM may have roles in graft rejection after kidney transplantation PMID: 23375291
    21. BTLA regulates human B cell responses and has implications for future development of therapies modulating B cells. PMID: 22903545
    22. The expression of BTLA has been observed on the surface of several kinds of cells within synovial tissues of RA patients, which indicates this signal might be involved in the regulation of local T cell activation and the pathogenesis of RA. PMID: 22691359
    23. These findings support role for BTLA and/or HVEM as potential, novel diagnostic markers of innate immune response/status and as therapeutic targets of sepsis. PMID: 22459947
    24. study described the expression and spatial distribution of HVEM and BTLA in rheumatoid arthritis synovial tissues, and results indicated that HVEM/BTLA may be involved in regulating the progress of joint inflammation PMID: 22179929
    25. BTLA-HVEM interactions impair minor histocompatibiility antigen-specific T cell functionality, providing a rationale for BTLA signaling blockade in post-stem cell transplantation. PMID: 22634623
    26. Added with PD-1 and Tim-3 blockades, BTLA blockade enhanced the expansion, proliferation, and cytokine production of NY-ESO-1-specific CD8(+) T cells. PMID: 22205715
    27. HVEM-BTLA cis complex provides intrinsic regulation in T cells serving as an interference mechanism silencing signals coming from the microenvironment. PMID: 21920726
    28. The results of a mutagenesis study of HVEM suggest that the CD160 binding region on HVEM was slightly different from, but overlapped with, the BTLA binding site. PMID: 21959263
    29. 590C single-nucleotide polymorphism of B- and T-lymphocyte attenuator was significantly associated with susceptibility to rheumatoid arthritis, but not to systemic lupus erythematosus or Sjogren's syndrome. PMID: 21403914
    30. BTLA expression on overall CD4(+) and CD8(+) T cells was progressively decreased in HIV-1 infection, which was directly correlated with disease progression and CD4(+) T-cell differentiation and activation PMID: 21592997
    31. In vitro blockade of the BTLA pathway augments allogeneic as well as cytomegalovirus-specific CD8-positive T cell proliferation, thereby enhancing the functional capacity of cytotoxic T lymphocytes in viral infections. PMID: 20693422
    32. BTLA gene polymorphisms may affect the sporadic breast cancer risk and prognosis in Chinese women in northeast of Heilongjiang Province PMID: 19585237
    33. Binding of HVEM to BTLA attenuates T cell activation, identifying HVEM/BTLA as a coinhibitory receptor pair. PMID: 15647361
    34. distinct herpesviruses target the HVEM-BTLA cosignaling pathway, suggesting the importance of this pathway in regulating T cell activation during host defenses. PMID: 16131544
    35. 2.8-A crystal structure of the BTLA-HVEM complex shows that BTLA binds the N-terminal cysteine-rich domain of HVEM and employs a unique binding surface PMID: 16169851
    36. BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. PMID: 16643847
    37. Cross-linking of BTLA with mAb 7D7 suppressed T lymphocyte proliferation, downregulated the expression of T cell activation marker CD25, and inhibited the production of interferon (IFN)-gamma, interleukin (IL)-2, IL-4, and IL-10. PMID: 17257317
    38. BTLA is an inhibitory coreceptor of the B cell receptor (BCR) signaling pathway that attenuates B cell activation by targeting the downstream signaling molecules Syk and B cell linker protein (BLNK). PMID: 19155498
    39. this study did not find any genetic contribution of the BTLA gene to the development of T1D and SLE in Japanese population. PMID: 19207938
    40. results suggest that down-regulation of the BTLA-HVEM pathway may be involved in germinal center B-cell activation. PMID: 19762537
    41. the HVEM-BTLA cis-complex competitively inhibits HVEM activation by ligands expressed in the surrounding microenvironment, thus helping maintain T cells in the naive state. PMID: 19915044
    42. HVEM binds to B T lymphocyte attenuator (BTLA), an Ig family member, which inhibits T cell proliferation. PMID: 15568026

    顯示更多

    收起更多

  • 亞細胞定位:
    Cell membrane; Single-pass type I membrane protein.
  • 數據庫鏈接:

    HGNC: 21087

    OMIM: 607925

    KEGG: hsa:151888

    STRING: 9606.ENSP00000333919

    UniGene: Hs.445162



主站蜘蛛池模板: 色视频综合无码一区二区三区| 成人国内精品久久久久一区| 日本一区不卡高清更新二区| 99亚洲乱人伦aⅴ精品| 久久久久国产a免费观看rela| 国产激情精品一区二区三区| 国内少妇偷人精品免费| 日本午夜精品一区二区三区电影| 影音先锋无码a∨男人资源站| 国产精品无码a∨麻豆| 色欲色香天天天综合vvv| 性欧美高清come| 人妻熟人中文字幕一区二区| 看成年全黄大色黄大片| 亚洲一区二区无码影院| 在线观看无码av免费不卡软件| 国产婷婷色综合av蜜臀av| 尤物av无码色av无码| 亚洲综合小说另类图片五月天| 18成禁人视频免费| 鲁鲁网亚洲站内射污| 18禁黄网站禁片免费观看| 成年轻人电影www无码| 国产成人亚洲高清一区| 精品无码国产日韩制服丝袜 | 日韩精品国产另类专区| 国产人妻精品一区二区三首 | 牛和人交videos欧美| 国产一区二区三区免费观看在线 | 欧美xxxxx高潮喷水麻豆| 国产精品久久人妻无码网站蜜臀| 国产精品9999久久久久| 男受被做哭激烈娇喘gv视频| 久久视频在线视频| 麻豆果冻精东九一传媒mv| 精品无码成人片一区二区 | 欧美精品久久天天躁| 亚洲欧美精品suv| 在线资源天堂www| 最新日韩精品中文字幕| 亚洲国产成人综合精品|